Cargando…
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
INTRODUCTION: We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the p...
Autores principales: | Borgquist, Signe, Jögi, Annika, Pontén, Fredrik, Rydén, Lisa, Brennan, Donal J, Jirström, Karin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614512/ https://www.ncbi.nlm.nih.gov/pubmed/18808688 http://dx.doi.org/10.1186/bcr2146 |
Ejemplares similares
-
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
por: Brennan, Donal J, et al.
Publicado: (2011) -
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients
por: Gustbée, Emma, et al.
Publicado: (2015) -
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
por: Bengtsson, Erik, et al.
Publicado: (2014) -
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
por: Brennan, Donal J, et al.
Publicado: (2010) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023)